Advaxis, Inc.(NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Shelonitda S. Rose, M.D., as Vice President, Clinical Development. Dr. Rose brings to Advaxis more than 15 years of experience in medical oncology and hematology clinical research.
In her role as Vice President, Clinical Development, Dr. Rose will report to Advaxis’s Executive Vice President, Chief Medical Officer, David J. Mauro, MD, Ph.D., and will oversee clinical development programs for the Company’s Lm Technology™ platform. Advaxis has initiated three new clinical trials in 2015, including a combination study involving ADXS-PSA and Merck’s PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab). In addition, the Company expects to initiate six additional clinical trials by the end of year to evaluate its LmTechnology™ immunotherapy in cervical cancer, HPV-associated anal cancer and HER2 expressing solid tumors.
Most recently, Dr. Rose served as Director, Oncology Clinical Research for Merck & Co., Inc. She joined Merck in October 2010 and in her role was the medical monitor for multiple programs including KEYTRUDA, for which she was the clinical lead for Hodgkin Lymphoma studies. Dr. Rose also designed, authored and executed clinical studies, and developed the hematology strategy.
“Within the past year, Advaxis has made steps to continue to strengthen our immunotherapy platform, requiring someone with Shelonitda’s clinical expertise to manage our clinical development,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. “She brings a wealth of experience monitoring clinical studies and has prior operational experience with Merck’s KEYTRUDA, an agent we are exploring in combination with our immunotherapy candidate, ADXS-PSA. Her experience will be essential as we progress our combination studies and expand our clinical development program.”
Prior to joining Merck, Dr. Rose was the Program Director for the Hematology-Oncology Fellowship Program and an Associate Professor of Medicine and of Pathology and Transfusion Medicine at the University of Medicine and Dentistry of New Jersey (UMDNJ) – Robert Wood Johnson Medical School from 2002 to 2010, and Assistant Professor of Medicine in the Division of Hematology/Oncology at The Texas A&M University Health Science Center Medical School from 2000 to 2002. Dr. Rose is the author of several scientific articles in hematology and oncology. She holds a medical degree from Madurai Kamaraj University, Madurai Medical College, in Tamil Nadu, India, and completed a fellowship in hematology/oncology with the UMDNJ – Robert Wood Johnson Medical School.
In connection with her appointment, Dr. Rose received a one-time inducement award of 85,000 restricted shares, of which 21,250 (25%) are fully vested as of the grant date. The remaining shares vest annually over a three-year period. The Company approved the award as an inducement material to Dr. Rose entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). (Original Source)
Shares of Advaxis Inc closed yesterday at $19.04. ADXS has a 1-year high of $30.13 and a 1-year low of $2.50. The stock’s 50-day moving average is $22.56 and its 200-day moving average is $15.43.
On the ratings front, Advaxis has been the subject of a number of recent research reports. In a report issued on June 26, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on ADXS, with a price target of $30, which implies an upside of 57.6% from current levels. Separately, on June 25, MLV & Co.’s Ram Selvaraju reiterated a Buy rating on the stock and has a price target of $34.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Swayampakula Ramakanth and Ram Selvaraju have a total average return of 9.8% and 9.7% respectively. Ramakanth has a success rate of 41.5% and is ranked #931 out of 3692 analysts, while Selvaraju has a success rate of 47.0% and is ranked #458.
Advaxis Inc is a clinical development stage biotechnology company. The company is engaged in developing safe & effective immunotherapies for cancer & infectious diseases.